Covered recipient · General Payments record
NICOLAS VAUGHN
General Payments · PY2023–2024
$921.98
- Reported across 19 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $722.19 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $279.33 | 3 |
| ABBVIE INC. | $213.28 | 7 |
| Lundbeck LLC | $92.41 | 1 |
| Janssen Pharmaceuticals, Inc | $70.48 | 2 |
| Indivior Inc. | $36.92 | 2 |
| ITI, Inc. | $29.77 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
Program year 2024 2023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $32.38 | 03/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106274926 | CMS |
| ABBVIE INC. | $87.97 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106274928 | CMS |
| ABBVIE INC. | $5.58 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106274930 | CMS |
| ABBVIE INC. | $27.28 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106274932 | CMS |
| ABBVIE INC. | $25.02 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106274934 | CMS |
| ABBVIE INC. | $22.15 | 07/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106274936 | CMS |
| ABBVIE INC. | $12.90 | 07/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106274938 | CMS |
| Indivior Inc. | $13.24 | 02/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144539929 | CMS |
| Indivior Inc. | $23.68 | 06/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144539931 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $29.77 | 02/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143338471 | CMS |
| Janssen Pharmaceuticals, Inc | $35.48 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078100452 | CMS |
| Janssen Pharmaceuticals, Inc | $35.00 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078100868 | CMS |
| Lundbeck LLC | $92.41 | 08/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145977975 | CMS |
| Teva Pharmaceuticals USA, Inc. | $98.56 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151482321 | CMS |
| Teva Pharmaceuticals USA, Inc. | $80.73 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151482309 | CMS |
| Teva Pharmaceuticals USA, Inc. | $100.04 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151482311 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.